Business
PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief
HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical
About this update from Prf Technologies Ltd.
[{"type":"text","content":"HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update. Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Rita Keynan as Vice President of Pharmaceutical OperationsSigned a manufacturing services and quality agreement with a subcontractor for GMP manufacturing of clinical trial batches of PRF-110Continued to build the patent estate, which now includes fourteen issued patents around the world, the earliest of which do not expire until 2033Announced a $6 million private placement, expected to provide funding into Q2 2022 Ilan Hadar, Chief Executive Officer of PainReform, commented, “We are making rapid progress towards commencing our Phase 3 clinical trials of PRF-110. Our first planned trial is for bunionectomy surgery. On the heels of the bunionectomy trial, we plan to commence our second Phase 3 trial for the treatment of hernia. In addition, we recently announced the appointment of Lotus Clinical Research as our clinical research organization to conduct the two clinical trials under the leadership of Dr. Neil Singla, one of the preeminent experts in analgesic protocol design. We also recently announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations, who brings over 25 years of experience in the pharmaceutical industry and will be an important addition to the team as we prepare to commence our Phase 3 pivotal trials for PRF-110. Most recently, we signed a manufacturing services and quality agreement with a subcontractor for manufacturing of regarding GMP manufacturing clinical trial batches of PRF-110.” Mr. Hadar concluded, “I am excited about the outlook for 2021 and look forward to a number of key upcoming catalysts that we believe will further enhance shareholders’ value, including the start of enrolment and dosing of ...